T. Rowe Price reports a Pacific Biosciences (PACB) stake; New Horizons has a 5.2% interest.
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
T. Rowe Price Associates, Inc. has reported a 10.8% beneficial ownership stake in Pacific Biosciences of California, Inc. (PACB), amounting to 33,445,993 shares, while denying direct beneficial ownership. The firm's New Horizons Fund specifically holds an interest in 15,591,500 shares, representing 5.2% of the class. This disclosure was made via a Schedule 13G SEC filing on November 6, 2026.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.